NEW YORK, March 03, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Facebook, Inc. (NASDAQ:FB) between May 5, 2014 and December 9, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. To get more information go to:
http://www.zlk.com/pslra/facebook-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Facebook’s metrics to calculate the average time users spent watching videos was overestimated by between 60% and 80%; (2) Facebook provided inaccurate statistics to advertisers regarding the amount of activity their ads received on the Website; and (3) as a result, the Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you suffered a loss in Facebook you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 



